Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors – Pipeline Review, 2019

Fibroblast Growth Factor Receptor 4 (FGFR4) is a tyrosine kinase receptor present on the cell surface and encoded by the FGF genes. Fibroblast growth factor receptor 4 plays a vital role in cell processes such as regulating cell proliferation, migration, differentiation, bile acid biosynthesis, and metabolism. The members of the FGFR family differ in their tissue distribution and ligand specificity. Hence, the activation of FGFR4 is highly associated with amplification of FGF19, a ligand specific for FGFR4.

In the case of hematologic malignancies and solid tumors, the FGFR4 acts as an oncogene driving factor due to an increased level of FGF19 specific ligand. FGFR4 inhibitors are emerging as a potential therapeutic agent for the treatment of various types of cancer. Targeting FGFR4 through small-molecule inhibitors can be more feasible and can be developed using structure-guided drug design.

FGFR4 Inhibitors are attracting huge pharmaceutical and research focus on the development of novel targeted therapy against cancer. Furthermore, the rising prevalence of cancer is also one of the major factors in encouraging pharmaceutical companies to develop novel drugs. For instance; Novartis AG has initiated phase 1 study on FGF401 for the treatment of patients with hepatocellular carcinoma.

At present, around 60% of the pipeline candidates for Fibroblast Growth Factor Receptor 4 (FGFR4) are in the phase-1 stage. Majority of the studies have been sponsored by pharmaceutical companies.

Report Description

The report on ‘Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors.

The report on ‘Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary